"Prof. Dr. Hulya Ayar Kayali completed her PhD in Biochemistry at Dokuz Eylul University, Department of Chemistry, in 2005. She was awarded the title of Associate Professor in 2008 and has been a Professor in the Department of Biochemistry at Dokuz Eylul University since 2014. Additionally, she is a Principal Investigator at the Ayar-Kayali Biopharmaceutical Technology and Bioanalysis laboratory at the Izmir Biomedicine and Genome Center. In 2020, she also founded ID Biofarma Biotechnology Industry Trade Limited Company. Prof. Dr. Ayar Kayali has supervised more than 10 master’s and 5 PhD graduates. She is currently mentoring 3 master’s students and 6 doctoral candidates, in addition to collaborating with three postdoctoral researchers. She has made significant contributions to the scientific literature, having published over 50 research papers. Her research group focuses on therapeutic antibodies, innovative drug research, and multi-targeted drug delivery systems. The team specifically explores metabolic pathways and cancer cell surface-targeting strategies for the precise delivery of exosome-based drug delivery systems. To produce therapeutic monoclonal antibodies, they employ mammalian cell culture techniques. Advanced analytical methods, including Ultra Performance Liquid Chromatography (UPLC), Mass Spectrometry, Flow Cytometry, Electron Microscopy, and Surface Plasmon Resonance (SPR), are used for comprehensive antibody characterization. A unique feature of Prof. Dr. Ayar Kayali’s research is her close collaboration with the university hospital, providing access to patient samples such as blood, urine, and biopsy materials. This collaboration enables her team to conduct in-depth analyses of metabolic pathways, offering valuable insights for the refinement of drug delivery systems. Additionally, her group is working on developing various diagnostic kits, including glycan analysis kits and disease-specific diagnostic tools."